Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin in Hepatitis C with Severe Fibrosis
NCT00148837Phase 2Completed
- Sponsor
- ANRS
- Start
- Sep 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C (HCV) and fibrosis comparing prazosin with placebo (2 arms). Primary endpoint: Proportion of patients presenting a decrease of fibrosis at 96 weeks. Started Sep 2004; status: completed.
02
Drugs
prazosin
03
Conditions
hepatitis C (HCV)fibrosis
Beyond the preview
Go deeper on NCT00148837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148837.